Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Janus faces of ras: Anti or pro-apoptotic?
N. Arber
*
*
Corresponding author for this work
Internal Medicine
Tel Aviv Sourasky Medical Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Janus faces of ras: Anti or pro-apoptotic?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Apoptosis
100%
Pro-apoptotic
100%
Human Cancer
100%
Anti-apoptotic
100%
Janus Face
100%
Clinical Trials
50%
Cell Cycle Checkpoint
50%
Novel Therapeutics
50%
Cell Population
50%
Cell Death
50%
Tumor
50%
Therapeutic Modalities
50%
Cell Proliferation
50%
Oncogene
50%
Gastrointestinal Tract
50%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
50%
Cell Loss
50%
Ras Signaling
50%
Tissue Homeostasis
50%
Farnesyltransferase Inhibitor
50%
Ras Expression
50%
Population Homeostasis
50%
Autonomous Cell
50%
Biochemistry, Genetics and Molecular Biology
Homeostasis
100%
Cell Cycle Checkpoint
50%
Cell Death
50%
Clinical Trial
50%
Cell Proliferation
50%
Oncogene
50%
Farnesyltransferase
50%
Gastrointestinal Tract
50%
Cell Loss
50%
Medicine and Dentistry
Ras Signaling
100%
Malignant Neoplasm
40%
Homeostasis
40%
Programmed Cell Death
40%
Therapeutic Modality
20%
Neoplasm
20%
Clinical Trial
20%
Cell Death
20%
Cell Proliferation
20%
Gastrointestinal Tract
20%
Oncogene
20%
Cell Population
20%
Anti-Inflammatory Drug
20%
Cell Loss
20%
Cell Cycle Checkpoint
20%
Farnesyltransferase Inhibitor
20%
Neuroscience
Face
100%
Cell Death
50%
Cell Proliferation
50%
Anti-Inflammatory
50%
Oncogene
50%
Cell Loss
50%
Cell Cycle Checkpoint
50%
Farnesyltransferase Inhibitor
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Clinical Trial
50%
Neoplasm
50%
Anti-Inflammatory Drug
50%
Protein Farnesyltransferase Inhibitor
50%